Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.

Zhou X, Qiao G, Wang X, Song Q, Morse MA, Hobeika A, Gwin WR, Ren J, Lyerly HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):365-372. doi: 10.1007/s00280-017-3500-9. Epub 2017 Dec 14.

PMID:
29242966
2.

In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.

Osada T, Kaneko K, Gwin WR, Morse MA, Hobeika A, Pogue BW, Hartman ZC, Hughes PF, Haystead T, Lyerly HK.

Clin Cancer Res. 2017 Dec 15;23(24):7531-7542. doi: 10.1158/1078-0432.CCR-17-1453. Epub 2017 Oct 9.

PMID:
28993342
3.

Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study.

Song Q, Ren J, Zhou X, Wang X, Song G, Hobeika A, Yuan Y, Lyerly HK.

Cytotherapy. 2018 Jan;20(1):126-133. doi: 10.1016/j.jcyt.2017.08.018. Epub 2017 Oct 4.

PMID:
28988693
4.

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.

Osada T, Morse MA, Hobeika A, Diniz MA, Gwin WR, Hartman Z, Wei J, Guo H, Yang XY, Liu CX, Kaneko K, Broadwater G, Lyerly HK.

Oncoimmunology. 2017 Apr 12;6(6):e1315495. doi: 10.1080/2162402X.2017.1315495. eCollection 2017.

5.

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.

Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, Huang L, Hobeika A, Yi X, Xia X, Guan Y, Song J, Ren J, Lyerly HK.

Clin Cancer Res. 2017 Sep 1;23(17):5066-5073. doi: 10.1158/1078-0432.CCR-17-0492. Epub 2017 Jun 13.

PMID:
28611200
6.

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.

Ren J, Gwin WR, Zhou X, Wang X, Huang H, Jiang N, Zhou L, Agarwal P, Hobeika A, Crosby E, Hartman ZC, Morse MA, H Eng K, Lyerly HK.

Oncoimmunology. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563. eCollection 2017.

7.

The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.

Song QK, Ren J, Zhou XN, Wang XL, Song GH, Di LJ, Yu J, Hobeika A, Morse MA, Yuan YH, Yang HB, Lyerly HK.

Oncotarget. 2015 Dec 1;6(38):41350-9. doi: 10.18632/oncotarget.5534.

8.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK.

J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.

PMID:
25839441
9.

Biomarkers and correlative endpoints for immunotherapy trials.

Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e287. Review.

10.

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK.

Ann Surg. 2013 Dec;258(6):879-86. doi: 10.1097/SLA.0b013e318292919e.

11.

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.

Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK.

Cancer Immunol Immunother. 2013 Aug;62(8):1293-301. doi: 10.1007/s00262-013-1400-3. Epub 2013 Apr 30.

12.

Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

Ren XR, Wei J, Lei G, Wang J, Lu J, Xia W, Spector N, Barak LS, Clay TM, Osada T, Hamilton E, Blackwell K, Hobeika AC, Morse MA, Lyerly HK, Chen W.

Breast Cancer Res. 2012 Jun 7;14(3):R89.

13.

Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.

Osada T, Morse MA, Hobeika A, Lyerly HK.

Semin Oncol. 2012 Jun;39(3):305-10. doi: 10.1053/j.seminoncol.2012.02.013. Review.

14.

Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.

Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, Yang XY, Hobeika A, Burnett B, Devi GR, Clay TM, Smith J, Kim Lyerly H.

Cancer Immunol Immunother. 2012 Nov;61(11):1941-51. doi: 10.1007/s00262-012-1248-y. Epub 2012 Apr 10.

15.

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA.

J Transl Med. 2012 Feb 10;10:28. doi: 10.1186/1479-5876-10-28. Erratum in: J Transl Med. 2013;11:82. Morse, Michael A [added].

16.

Increasing vaccine potency through exosome antigen targeting.

Hartman ZC, Wei J, Glass OK, Guo H, Lei G, Yang XY, Osada T, Hobeika A, Delcayre A, Le Pecq JB, Morse MA, Clay TM, Lyerly HK.

Vaccine. 2011 Nov 21;29(50):9361-7. doi: 10.1016/j.vaccine.2011.09.133. Epub 2011 Oct 12.

17.

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

Morse MA, Hobeika A, Serra D, Aird K, McKinney M, Aldrich A, Clay T, Mourich D, Lyerly HK, Iversen PL, Devi GR.

Cancer Gene Ther. 2012 Jan;19(1):30-7. doi: 10.1038/cgt.2011.63. Epub 2011 Oct 14.

PMID:
21997230
18.

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.

Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, Zhao B, Butler SA, Hobeika A, Osada T, Davis T, Clay T, Lyerly HK.

Clin Cancer Res. 2011 Jul 15;17(14):4844-53. doi: 10.1158/1078-0432.CCR-11-0891. Epub 2011 Jun 1.

19.

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R.

Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7.

20.

Depletion of human regulatory T cells.

Hobeika AC, Morse MA, Osada T, Peplinski S, Lyerly HK, Clay TM.

Methods Mol Biol. 2011;707:219-31. doi: 10.1007/978-1-61737-979-6_14.

PMID:
21287338
21.

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.

Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, Secord AA, Lyerly HK, Morse MA, Philip R.

Clin Exp Immunol. 2011 Mar;163(3):324-32. doi: 10.1111/j.1365-2249.2010.04298.x. Epub 2010 Dec 22.

22.

Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Lyerly HK.

Immunol Res. 2011 Apr;49(1-3):235-47. doi: 10.1007/s12026-010-8186-6.

23.

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK.

J Clin Invest. 2010 Sep;120(9):3234-41. doi: 10.1172/JCI42672. Epub 2010 Aug 2.

24.

An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, Morse MA, Lyerly HK, Clay TM.

Clin Cancer Res. 2010 Mar 1;16(5):1466-77. doi: 10.1158/1078-0432.CCR-09-2549. Epub 2010 Feb 23.

25.

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.

Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA.

Br J Cancer. 2010 Jan 5;102(1):124-33. doi: 10.1038/sj.bjc.6605364. Epub 2009 Dec 1.

26.

Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM.

Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995.

27.

Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.

Sun B, Kulis MD, Young SP, Hobeika AC, Li S, Bird A, Zhang H, Li Y, Clay TM, Burks W, Kishnani PS, Koeberl DD.

Mol Ther. 2010 Feb;18(2):353-60. doi: 10.1038/mt.2009.195. Epub 2009 Aug 18.

28.

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM.

Blood. 2008 Aug 1;112(3):610-8. doi: 10.1182/blood-2008-01-135319. Epub 2008 Jun 2.

29.

Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.

Hobeika A, Osada T, Serra D, Peplinski S, Hanson K, Tanaka Y, Niedzwiecki D, Chao N, Rizzieri D, Lyerly H, Clay T, Morse M.

Cytotherapy. 2008;10(3):289-302. doi: 10.1080/14653240801927040.

PMID:
18418774
30.

Current immunotherapeutic strategies in colon cancer.

Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK.

Surg Oncol Clin N Am. 2007 Oct;16(4):873-900, x. Review.

PMID:
18022550
31.

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM.

J Transl Med. 2007 Sep 6;5:42.

32.

Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.

Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA.

Expert Opin Biol Ther. 2007 Apr;7(4):449-60. Review.

PMID:
17373897
33.

NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.

Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA.

Cancer Immunol Immunother. 2006 Sep;55(9):1122-31. Epub 2005 Nov 5.

PMID:
16273350
34.

Recent developments in therapeutic cancer vaccines.

Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T.

Nat Clin Pract Oncol. 2005 Feb;2(2):108-13. Review.

PMID:
16264883
35.

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.

Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.

Clin Cancer Res. 2005 Apr 15;11(8):3017-24.

36.

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK.

J Transl Med. 2005 Feb 21;3(1):9.

37.

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM.

J Immunother. 2005 Jan-Feb;28(1):63-72.

PMID:
15614046
38.

Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.

Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK.

Cancer Invest. 2003 Jun;21(3):341-9.

PMID:
12901279
39.

Proteomics for monitoring immune responses to cancer vaccines.

Mosca PJ, Lyerly HK, Ching CD, Hobeika AC, Clay TM, Morse MA.

Curr Opin Mol Ther. 2003 Feb;5(1):39-43. Review.

PMID:
12669469
40.

HER2 dendritic cell vaccines.

Morse MA, Clay TM, Colling K, Hobeika A, Grabstein K, Cheever MA, Lyerly HK.

Clin Breast Cancer. 2003 Feb;3 Suppl 4:S164-72.

PMID:
12620155
41.

Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.

Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA.

J Leukoc Biol. 2002 Sep;72(3):546-53.

PMID:
12223523
42.

Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.

Morse MA, Rizzieri D, Stenzel TT, Hobeika AC, Vredenburgh JJ, Chao NJ, Clay TM, Mosca PJ, Lyerly HK.

J Hematother Stem Cell Res. 2002 Aug;11(4):659-68.

PMID:
12201954
43.

Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer.

Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM.

Int J Cancer. 2001 Dec 15;94(6):834-41.

44.

Surrogate markers of response to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK.

Expert Opin Biol Ther. 2001 Mar;1(2):153-8.

PMID:
11727526
45.

Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA.

Crit Rev Immunol. 2001;21(1-3):287-97. Review.

PMID:
11642610
46.

Superantigens: the good, the bad, and the ugly.

Torres BA, Kominsky S, Perrin GQ, Hobeika AC, Johnson HM.

Exp Biol Med (Maywood). 2001 Mar;226(3):164-76. Review.

PMID:
11361034
47.

Assays for monitoring cellular immune responses to active immunotherapy of cancer.

Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA.

Clin Cancer Res. 2001 May;7(5):1127-35. Review.

48.

Monitoring cellular immune responses to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK.

Curr Opin Mol Ther. 2001 Feb;3(1):45-52. Review.

PMID:
11249731
49.

Direct detection of cellular immune responses to cancer vaccines.

Mosca PJ, Hobeika AC, Clay TM, Morse MA, Lyerly HK.

Surgery. 2001 Mar;129(3):248-54. Review.

PMID:
11231452
50.

Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.

Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, Hobeika A, Mosca P, Clay T, Cumming RI, Fisher E, Clavien P, Proia AD, Niedzwiecki D, Caron D, Lyerly HK.

J Clin Oncol. 2000 Dec 1;18(23):3883-93.

PMID:
11099317

Supplemental Content

Loading ...
Support Center